The Hook: A Big Trial That Mostly Found Nothing
Carnosine capsules are marketed as a muscle-endurance booster. A new 299-person randomized, placebo-controlled trial put that claim to the test, and most of the outcomes came back flat. A couple of subgroup signals did turn up, and they are worth understanding without overselling them.
The study was published in the Journal of the International Society of Sports Nutrition by a University of Louisville and Bellarmine University team led by O'Toole and Bhatnagar. The authors note that carnosine and its precursor, beta-alanine, are widely used as performance supplements, yet carnosine's efficacy "has not been rigorously evaluated."
What They Actually Did
- Design: Placebo-controlled randomized clinical trial
- Sample size: 299 participants
- Dose: 2 g of carnosine per day, taken as capsules
- Duration: About 12 weeks, with testing at baseline, about 6 weeks, and 12 weeks
- Tests: Hand grip strength, bilateral calf raises to exhaustion, a 2-minute step test, and gait speed
- Extras: Blood and urine were collected at each visit
The researchers calculated both absolute and percent changes from baseline for each physical function measure and compared carnosine with placebo.
The Headline Result: Mostly a Null
Across the performance measures, carnosine did not beat placebo in the overall comparison. The authors report no significant differences (p < 0.05) for any measure other than the two subgroup findings below. That includes grip strength and gait speed, and the abstract reports no overall win for the step test or calf raise either.
If you wanted a clean "carnosine boosts endurance in everyone" result, this trial doesn't deliver it.
The Two Subgroup Hints
1. Calf raises in adults under 40 (6 weeks). Carnosine users under 40 did more bilateral calf raises to exhaustion than placebo users (p = 0.018).
2. Step test in men over 40 (12 weeks). Men over 40 taking carnosine completed more steps in the 2-minute step test (p = 0.010). Across all men on carnosine, the effect was only a trend (p = 0.06).
The authors conclude that benefits appeared limited to males and to select age groups, and that carnosine is "likely to have beneficial effects in those undertaking short-term repetitive movements."
Why You Should Read Those Hints Cautiously
This is where honesty matters more than hype.
- Subgroup analyses are fragile. Slicing a trial by age and sex creates many comparisons. With enough slices, some p-values will dip below 0.05 by chance. The abstract doesn't mention any correction for multiple testing.
- The pattern is scattered. One signal is in younger people at 6 weeks on a calf test. The other is in older men at 12 weeks on a step test. There is no single consistent story across time points, tests, or groups.
- A trend isn't a finding. The p = 0.06 result in all men does not meet the study's own threshold.
- The conclusion runs ahead of the data. "Improves muscular and cardiorespiratory endurance" in select groups is a stronger statement than a mostly null trial with two isolated hits supports.
- Details are missing from the abstract. It doesn't give participant demographics, effect sizes, adherence, or whether the subgroup analyses were pre-specified. I can't say more about them than that.
The best reading is that these are hypothesis-generating signals, not proof.
Carnosine vs. Beta-Alanine: An Honest Comparison
The trial tested carnosine, not beta-alanine, and it did not compare the two head to head. The following context comes from outside this paper.
Carnosine is made of beta-alanine and histidine. Beta-alanine is generally considered the rate-limiting building block for muscle carnosine, which is why sports nutrition has focused on it. Common beta-alanine protocols use several grams per day over weeks, often split into smaller doses because high single doses can cause tingling (paresthesia). The research on beta-alanine is larger and more established, and it points to modest benefits mainly in high-intensity efforts lasting roughly one to several minutes.
What this trial adds is a large, placebo-controlled test of oral carnosine at 2 g/day in a broad sample, and the result was largely null. It doesn't show that carnosine is useless. It does mean that the case for carnosine over the better-studied beta-alanine isn't strengthened by these data.
Practical Takeaways
Dose: The trial used 2 g/day of carnosine. That is the only dose tested, so it is the only one this study can speak to.
Timing: The abstract doesn't specify time of day or relation to workouts. Don't treat any specific timing protocol as evidence-based from this paper.
Duration: The calf-raise signal appeared at about 6 weeks and the step-test signal at about 12 weeks, but neither is a reliable timeline given the caveats above.
Who might consider it: Anyone curious who accepts that the evidence is thin. The authors suggest the most plausible benefit is for short-term repetitive movement tasks, with possible signals in adults under 40 (calf raises) and men over 40 (step test).
- Anyone hoping for grip strength or maximal strength gains. The trial found nothing there.
- Anyone expecting gait speed improvements. Nothing was found there either.
- Women expecting a boost. The authors say benefits appeared limited to males, though that finding is itself subgroup-based.
- Anyone on a tight budget who would do better spending on training, sleep, and protein.
Anyone who is pregnant, has a medical condition, or takes medication should talk to a clinician before starting any supplement. The abstract doesn't address those groups.
Bottom Line
A 299-person randomized trial of 2 g/day carnosine found no overall edge over placebo across grip strength, calf raises, step test, and gait speed. The only wins were a calf-raise improvement in people under 40 and a step-test improvement in men over 40. Those findings are interesting, but they are subgroup results that need replication before anyone should treat them as established. The authors report no conflicts of interest.
